Navigation Links
Halozyme Appoints Jeffrey W. Henderson To Board
Date:8/5/2015

SAN DIEGO, Aug. 5, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of Jeffrey W. Henderson to its board of directors. Henderson brings nearly 30 years of financial, commercial and pharmaceutical industry expertise to the board, most recently serving for almost 10 years as chief financial officer of $100-billion health care products and services company, Cardinal Health.

"We are delighted to appoint an industry executive of Jeff's caliber to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "Jeff brings great depth from his business experience in strategy, finance, M&A and commercial operations that will complement our board's expertise as we grow the company and prepare for the potential commercialization of our investigational new oncology drug, PEGPH20."

Henderson served as CFO of Cardinal Health from 2005 until late last year, playing a key role in the company's growth and transformation. During his tenure, the company acquired more than 30 companies, spun-off or sold multi-billion-dollar businesses and expanded into new geographies and market segments. In addition to his financial responsibilities, Henderson also managed commercial operations in China and Canada.

Prior to Cardinal Health, Henderson was president and general manager of Eli Lilly Canada Inc. and vice president and corporate controller of Eli Lilly & Co. He joined Lilly in 1998 as vice president and corporate treasurer. His prior experience included 10 years at General Motors Corp., where he served executive and managerial posts in Great Britain, Singapore, New York and Canada. He received his Bachelor of Science degree in electrical engineering from Kettering University, Flint, Mich., and his Master of Business Administration degree from Harvard Graduate School of Business Administration. Henderson is a native of St. Catharines, Ontario, Canada.

About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen and AbbVie for its drug delivery platform, ENHANZE™, which enables biologics and small molecule compounds that are currently administered intravenously to be delivered subcutaneously. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.

Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the Company's future expectations and plans for growth in 2015, the development and commercialization of product candidates and the potential benefits and attributes of such product candidates and expected financial outlook for 2015) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected expenditures and costs, unexpected fluctuations or changes in revenues from collaborators, unexpected results or delays in development and regulatory review, regulatory approval requirements, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 11, 2015.

Contacts:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com

Jim Mazzola
Halozyme Therapeutics
858-704-8122
ir@halozyme.com

Logo - http://photos.prnewswire.com/prnh/20100302/LA63139LOGO

 


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
2. Halozymes Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer
3. Halozyme to Host Second Quarter 2013 Financial Results Conference Call
4. Halozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) Formulation with rHuPH20
5. Halozyme Reports Second Quarter 2013 Financial Results
6. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
7. Halozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress
8. Halozyme Therapeutics To Present At The BioCentury Newsmakers In The Biotech Industry Conference
9. Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to Halozyme from Roche
10. Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013
11. SWOG Initiates Randomized Phase 2 Clinical Trial of Halozymes PEGPH20 in Combination with modified FOLFIRINOX for Advanced Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2019)... ... 17, 2019 , ... AssuriCare LLC , an innovation ... , the first and most compliant online management platform developed for registries ... and caregiver relationship management. RegistryConnect is available only to home care companies operating ...
(Date:9/17/2019)... ... 17, 2019 , ... Today, in partnership with Lehman College, ... consent with student and faculty from The City University of New York (CUNY). ... MPH; Elise Schuster, MPH; Raffaele M. Bernardo, DO, FACP, AAHIVS and Stuart Chen-Hayes, ...
(Date:9/17/2019)... OBISPO, Calif. (PRWEB) , ... September 17, 2019 , ... Summer is a time for ... it is good for our teeth and gums. Dr. Douglas Ng, family dentist in ... Warm weather is the time for ice cream, and popsicles and ice-filled cold drinks to ...
Breaking Medicine Technology:
(Date:9/17/2019)... ... September 17, 2019 , ... Milwaukee-area dealership Hall Cars has hosted an annual event each fall ... event, entitled “Drive Out Cancer,” entails that for every vehicle purchased from Sept. 17 to ... event lasts for 50 days, it has also been referred to as, “50 for 50.” ...
(Date:9/17/2019)... Calif. (PRWEB) , ... September 17, 2019 , ... ... CE Mark for Europe and the 21st Century Cures Act in the US, ... surgery, radiology, and pain management. Using images from existing MRI equipment to ...
(Date:9/17/2019)... TN (PRWEB) , ... September 17, 2019 , ... ... Periodontics and Dental Implants welcome patients with missing teeth in Chattanooga, TN for ... completed by a periodontist in as little as one day, providing a permanent ...
(Date:9/17/2019)... (PRWEB) , ... September 17, 2019 , ... Lubin ... reception fundraiser. Gather for GRIN2B will be held at Found Kitchen and ... , Proceeds will help fund research on GRIN2B-Related Neurodevelopmental Disorder, a rare condition that ...
(Date:9/17/2019)... ... September 17, 2019 , ... Genomenon today ... the goal of providing resources to assist researchers and encourage pharmaceutical companies to ... causing abnormal iron deposits in the brain. , BPAN Warriors is an ...
Breaking Medicine News(10 mins):